Jul. 12 at 1:58 AM
Upcoming
$RNXT Catalysts
Drug : RenovoGem - (TIGeR-PaC) Locally advanced pancreatic cancer (LAPC)
Stage : Phase 3
Status : Ongoing
Next Catalyst : Interim Data
Catalyst Date : Q3 2025
Phase 3 second interim analysis due in 3Q 2025, with a DMC meeting in 2H 2025. Phase 3 PK data presented at ASCO GI showed that intra-arterial delivery of gemcitabine via TAMP is a targeted treatment option to potentially improve local drug potency and treatment effectiveness, noted January 24, 2025.
$RNXT Drug Pipeline
Drug RenovoGem - (CouGar) Unresectable locally advanced extrahepatic cholangiocarcinoma (eCCA)
Stage Phase 3
Status Enrollment Initiation —
Catalyst Date
Phase 3 trial first clinical site initiated, noted December 21, 2023.
Drug : RenovoGem Cholangiocarcinoma (bile duct cancer) or eCCA
Stage : Phase 2/3
Status : Ongoing —
Catalyst Date
Phase 2/3 trial first patient dosing expected in 2023.
